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Background: Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal
stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST
patients with some “very high-risk” factors for more precise prognostic indicator, and possible association with efficiency
of imatinib adjuvant therapy.
Methods: Clinicopathological data were confirmed by pathological diagnosis and clinical records. Recurrence-free
survivals (RFS) were evaluated in 370 GIST patients (212 cases as test cohort and 158 cases as validation cohort)
and 48 high-risk GISTs with imatinib adjuvant therapy after R0 resection.
Results: Mitosis count > 10/50 high-power fields (HPF) and serosal invasion are independent prognostic factors for
RFS of GIST patients. Mitosis count > 10/50HPF and serosal invasion can sub-divide high-risk GIST patients effectively
and significantly improve the area under the curve (AUC) of receiver operating characteristics (ROC) curve for prognostic
indicator both in test and validation cohort. Patients with serosal invasion after R0 resection showed a poorer prognosis
with imatinib adjuvant therapy.
Conclusions: Sub-division of high-risk GIST patients helps to more precisely predicting the prognosis. Serosal invasion
may be an adverse predictive factor in high-risk patients and imatinib treatment outcome.
Keywords: Gastrointestinal stromal tumor, Mitosis, Serosal invasion, PrognosisBackground
Gastrointestinal stromal tumor (GIST) accounts for more
than 80% of all gastrointestinal mesenchymal tumors [1].
As it ranks below only gastric and colorectal cancers, GIST
is among the most common types of gastrointestinal
tumors. Recently, the incidence of GIST has gradually
increased [2-4] and there are more than 5000 newly
diagnosed cases each year since 2011 in the United
States [5].
Modified NIH criteria based on NIH consensus cri-
teria is wildly accepted as risk-stratification scheme for* Correspondence: caohuishcn@hotmail.com; zzhang@shsci.org
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unless otherwise stated.GIST and four categories from very low to high risk are
used to predict prognosis of GIST patients. The mitosis
count, tumor size, tumor site and tumor rupture are im-
portant prognostic predictors in this scheme [6,7]. How-
ever, the clinical behaviors and the outcomes of GIST
still vary even in the same group of the risk, especially in
the patients with high-risk of recurrence. With wide ap-
plication of imatinib mesylate (IM) in clinical practice
for GIST, the mortality rate of GIST patients has de-
creased significantly [8]. Nevertheless, the recurrence
and metastasis rates, especially for the patients at high-
risk stage, remain high [8-10].
Because unclear biological behaviors and high recur-
rence rates in high-risk GIST patients, some of them
suffer worse prognosis than others even they are classi-
fied into the same category with the same treatment. To
more precisely predict prognosis and possible associ-
ation with efficiency of imatinib adjuvant therapy fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of GIST patients in test and







≤ 50 36 (17.0%) 37 (23.4%) 0.124
> 50 176 (83.0%) 121 (76.6%)
Gender
Male 114 (53.8%) 85 (53.8%) 0.996
Female 98 (46.2%) 73 (46.2%)
Tumor site
Stomach 129 (60.8%) 82 (51.9%) 0.094
Small bowel 48 (22.6%) 54 (34.2%)
Colon 10 (4.7%) 8 (5.1%)
Others 25 (11.9%) 14 (8.9%)
Tumor size (cm)
≤ 2.0 20 (9.4%) 16 (10.1%) 0.408
2.1-5.0 100 (47.2%) 61 (38.6%)
5.1-10.0 59 (27.8%) 54 (34.2%)
> 10.0 33 (15.6%) 27 (17.1%)
Mitoses per 50 HPFs
≤ 5 175 (82.5%) 118 (74.7%) 0.078
6-10 23 (10.8%) 19 (12.0%)
> 10 14 (6.7%) 21 (13.3%)
Modified NIH criteria
Very low risk 18 (8.5%) 14 (8.9%) 0.087
Low risk 96 (45.3%) 56 (35.4%)
Intermediate risk 38 (17.9%) 24 (15.2%)
High risk 60 (28.3%) 64 (40.5%)
Serosal invasion
Yes 23 (10.8%) 20 (12.7%) 0.591
No 189 (89.2%) 138 (87.3%)
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GIST patients with some “very high-risk” factors, such
as primary sites not from stomach, tumor size > 10 cm,
mitosis count > 10/50HPF and serosal invasion, a com-
mon pathological diagnosis in malignant tumors. Related




This project was approved by ethics committee of Ren Ji
Hospital, Shanghai Jiao Tong University School of Medi-
cine for the use of samples, approval No. 2012031. In-
formed consents were obtained from all patients before
study inclusion.
Patients and procedures
The patient inclusion criteria were as follows: 1) a dis-
tinct pathologic diagnosis of GIST; 2) underwent R0 re-
section, R0 resection in our study defined as margin-free
resection and no metastasis detected before and during
the surgery; 3) no radiotherapy, chemotherapy, nor other
anti-cancer therapies prior to the surgery; and 4) avail-
ability of complete clinicopathologic and follow-up data.
The patient exclusion criteria were as follows: 1) under-
went R1/2 (margin-positive) resection; and 2) locally ad-
vanced GIST. The parameters, including patient age,
gender, tumor site, tumor size, number of mitoses/50
high-power fields (HPF) and serosal invasion, were re-
corded in the official pathology database. Cases with
tumor rupture were not enrolled in our study because
insufficient data in our clinical records. The risk of ag-
gressive tumor behavior was calculated according to the
modified NIH criteria, which classified GIST into very
low, low, intermediate, and high-risk categories.
In patients without imatinib adjuvant therapy and met
the criteria in our study, were divided into two cohorts
by different surgical time periods for getting more reli-
able results as a single center research. As the test co-
hort, 212 cases of GISTs (male 114 and female 98 cases;
mean age: 61 years) were collected retrospectively from
patients who underwent surgeries at Ren Ji Hospital,
Shanghai Jiao Tong University School of Medicine from
January 2010 to May 2013. In parallel, we retrospectively
assessed another validation cohort collected 158 cases
(male 85 and female 73 cases; mean age: 59 years) from
the same hospital between January 2004 and December
2009. More details of clinic-pathological characteristics
of test and validation cohort could refer to Table 1.
Complete follow-up data until December, 2013, for pa-
tients in test and validation cohort were available. RFS
was calculated from the date of tumor resection until
the detection of tumor recurrence or last observation.
The median follow-up of the test cohort was 30 months(range, 7–49 months). In the validation cohort, the me-
dian follow-up was 69 months (range, 12–106 months).
Computed tomography (CT) and/or magnetic resonance
imaging (MRI) were used to verify tumor recurrence in
suspected cases.
Patients with serosal invasion in our study were con-
firmed by the pathological diagnosis as GIST invading
the layer of serosa, including the serosa from the surface
of adjacent organs or tissues. An extended local excision
around serosal invasion area was conducted for R0 re-
section. The locally advanced GIST explicitly indicated
by CT or MRI before the surgery was excluded in our
study because this kind of GISTs not only penetrate
serosa layer but also invade parenchyma of adjacent
organ always leading to R1/2 resection with very poor
prognosis. Neoadjuvent imatinib therapy has already been
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ESMO and NCCN guidelines. Our study aimed to
figure out the prognostic value of GIST which just only
invading serosal layer, so local advanced GIST were
excluded in our study.
The criterion of imatinib adjuvant therapy after R0 re-
section in our study required at least 12 months uninter-
rupted drugs taking with 400 mg/day. 48 high-risk cases
met the criteria of imatinib adjuvant therapy since 2008
in our study. The follow-up median of the patients with
imatinib therapy was 38 months (range, 16 - 71 months);
KIT and PDGFR gene analysis showed 45 cases with KIT
exon 11 and 3 cases with exon 9 mutation, and without
any PDGFR gene mutation detected.Statistical analysis
Statistical analyses were conducted using SPSS for Win-
dows (version 17.0) and MedCalc (version 11.4.2.0). For
comparisons, one-way analyses of variance and chi-
squared tests were performed when appropriate. RFS
was calculated according to the Kaplan-Meier method.
The log-rank test was used to compare the survival distri-
butions. Univariate and multivariate analyses were based on
the Cox proportional hazards regression model. Only vari-
ables that were significantly different in univariate analysis
were entered into the next multivariate analysis. ReceiverFigure 1 Pathological diagnoses of serosal invasion in GISTs by Hema
serosa layer. (B) Intestinal GIST invading the serosa of adjacent colon. (C) G
invading the peritoneum.operating characteristics (ROC) curves were constructed to
assess sensitivity, specificity, and respective areas under the
curves (AUCs) with 95% CI. All statistical tests were 2-
sided. P-value differences <0.05 were considered statistically
significant.Results
Mitosis count > 10/50HPF and serosal invasion are
independent prognostic factors for recurrence-free
survival of GIST patients
Characteristics of GIST patients in test and validation
cohort were shown in Table 1, chi-squared tests showed
there were no differences between the test and validation
cohorts in reported variables. The pathological diagnoses
of serosal invasion in GISTs by Hematoxylin-Eosin stain-
ing were shown in Figure 1. Univariate analysis showed
that tumor size (≤10, > 10 cm), mitosis count (≤10,
> 10/50 HPF) and serosal invasion were prognostic pre-
dictors for RFS both in the test and validation cohort.
Tumor site (stomach or no stomach) was identified as
a prognostic predictor only in the test cohort, but not
in the validation (Table 2). Furthermore, the multivari-
ate analysis found that mitosis count > 10/50 HPF and
serosal invasion were independently unfavorable prog-
nostic factors for RFS both in test and validation co-
hort (Table 3).toxylin-Eosin staining. (A) Intestinal GIST invading the primary
astric GIST invading the pancreatic capsule. (D) Intestinal GIST
Table 2 Univariate analyses of factors by cox regression model associated with recurrence-free survival (RFS) in test
and validation cohort (*, P < 0.05; **, P < 0.01)
Test cohort Validation cohort
Variable RFS hazard ratio (95% Cl) P value RFS hazard ratio (95% Cl) P value
Age (≤50, > 50) 0.463 (0.178-1.206) 0.115 3.673 (1.126-11.983) 0.031*
Gender (male, female) 0.594 (0.237-1.489) 0.266 0.342 (0.161-0.728) 0.005**
Tumor site (stomach, no stomach) 9.629 (2.820-32.879) <0.001** 1.760 (0.900-3.440) 0.098
Tumor size (≤10, > 10 cm) 8.732 (3.604-21.154) <0.001** 5.392 (2.787-10.430) <0.001**
Mitosis count (≤10, > 10/50 HPF) 13.459 (5.470-33.115) <0.001** 8.462 (4.335-16.519) <0.001**
Serosal invasion (Yes, No) 20.531 (8.170-51.596) <0.001** 7.706 (3.938-15.081) <0.001**
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sub-divide high-risk GIST patients effectively and
significantly to improve the prognostic indicator
Since the aforementioned factors were prognostic pre-
dictors or independently unfavorable prognostic factors
for RFS of GIST patients, the further study was focused
on whether these factors can sub-divide high-risk GIST
patients and improve the AUC of the ROC curve for
prognostic indicator. To test our hypothesis, the high-
risk GIST patients were divided into the following
sub-groups according to tumor size (≤10 cm vs
> 10 cm subgroup), mitosis count (≤10 HPF vs > 10/50
HPF subgroup) and serosal invasion (serosal invasion
vs no serosal invasion subgroup). RFS of GIST patients
in test and validation cohort classified by modified
NIH criteria were shown in Figure 2A and B. Log-rank
test showed that tumor size (≤10 or > 10 cm) can not
sub-divide high-risk group effectively both in test and
validation group (P > 0.05) (Figure 2C and D). Mitosis
count > 10/50 HPF and serosal invasion can signifi-
cantly sub-divide high-risk group as unfavorable prognos-
tic factors both in test and validation group (P < 0.05)
(Figure 2E, F, G and H).
ROC analysis showed that subdivided mitosis count
or serosal invasion based on modified NIH criteria can
improve modified NIH criteria for prognostic indicator
in GIST. AUC of subdivided mitosis count (0.885
for test cohort and 0.884 for validation cohort) were
higher than that of modified NIH criteria (0.853 for
test cohort and 0.846 for validation cohort) with sig-
nificantly difference both in the test and the validation
cohort (P < 0.01). The AUC of serosal invasion (0.901Table 3 Multivariate analyses of factors by cox regression mo
and validation cohort (*, P < 0.05; **, P < 0.01)
Test cohort
Variable RFS hazard ratio (95% Cl)
Tumor size (≤10, > 10 cm) 1.525 (0.465-5.001)
Mitosis count (≤10, > 10/50 HPF) 3.388 (1.193-9.636)
Serosal invasion (Yes, No) 10.220 (2.862-36.493)for test cohort and 0.880 for validation cohort) were
also significantly higher in both the test and the valid-
ation cohort (P < 0.01) (Figure 3).Serosal invasion may act as a predictive factor for the
efficacy of imatinib adjuvant therapy
Since high-risk GIST patients after R0 resection indi-
cated adjuvant therapy of imatinib, we further investi-
gated whether mitosis count > 10/50 HPF or serosal
invasion could affect the efficacy of imatinib adjuvant
therapy. Kaplan-Meier survival analysis with log-rank
test showed there was no difference in RFS between
mitosis count > 10/50 HPF nor ≤ 10/50 HPF subgroup
with imatinib therapy (P = 0.115). But the RFS of pa-
tients with serosal invasion showed sharp decline of
the curve as opposed to those without serosal invasion,
indicating serosal invasion as unfavorable effect on
imatinib adjuvant therapy (P = 0.014) (Figure 4). The
multivariate analysis found that serosal invasion was
independently unfavorable prognostic factors for RFS
of the GIST patients with imatinib adjuvant therapy
(Table 4).Discussion
GIST has a wide various biological behaviors with malig-
nant potential, so it can not be precisely distinguished as
benign or malignant lesions. Mitotic index, tumor size,
tumor site and tumor rupture which are from modified
NIH criteria can be important prognostic predictors of
GISTs [6,7,11]. According to the NIH guidelines, all GISTs
might have malignant potential. Moreover the recurrencedel associated with recurrence-free survival (RFS) in test
Validation cohort
P value RFS hazard ratio (95% Cl) P value
0.486 2.084 (0.901-4.821) 0.086
0.022* 4.117 (1.845-9.185) 0.001**
<0.001** 2.960 (1.237-7.079) 0.015*
Figure 2 Prognostic significance by modified NIH criteria in test (A) and validation (B) cohort, tumor size sub-groups in test (C) and
validation (D) cohort, mitosis count sub-groups in test (E) and validation (F) cohort and serosal invasion sub-groups in test (G) and
validation (H) cohort in GISTs.
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Figure 3 ROC curve for modified NIH criteria versus tumor size sub-group, mitosis count sub-group and serosal invasion sub-group in
prognostic indicator in test (A) and validation (B) cohort. (**, P < 0.01).
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intermediate-, low- and very low-risk cases, and even in the
same high-risk classification, the clinical outcomes of GIST
patients are always variety in our approximate 10 years’
follow-up database [12,13]. For example, patients with
GIST invading local tissue or organ even if receiving
R0 resection always appear poor prognosis. On the
contrary, some cases with large tumor size but less mi-
tosis count and tumor well-encapsulated are no sign of
recurrence for a long time follow up (>5 years) without
imatinib adjuvant therapy. As we all know, there is no
perfect criteria which can predict the prognosis of the
disease with 100% accuracy, and there must be some
unrevealed room for improving or complementing the
current criteria.
The aim of this study is to find “very high-risk” factors
which can effectively sub-divide high-risk patients after R0
resection for more precisely predicting prognosis. Because
our purpose was for clinical application, the factors we
chose must be easily understandable, well-accepted and
feasible variables. Primary sites not from stomach, tumor
size > 10 cm and mitosis count > 10/50HPF were selected
by referring to modified NIH criteria [7], serosal invasion
was also selected in our study as a common pathological
diagnosis in malignant tumors.
Tumor rupture is a poor prognostic factor indicated
by modified NIH criteria. Tumor rupture are divided
into two clinical conditions, one is spontaneous tumor
rupture prior to operation, and another is a result of the
manipulation at surgery [14,15]. Tumor rupture was notenrolled in our study because insufficient data in our clin-
ical records. This situation was common in other centers as
in Joensuu et al.’s multi-center research in which data of
tumor rupture were unavailable from 53.2% cases in pooled
population-based cohort and 100% cases in validation [11].
Actually most patients with spontaneous tumor rupture be-
fore surgery frequently found having already accompanied
with miliary nodules as implantation metastasis and impos-
sible for R0 resection were excluded in our study. Another
condition, if iatrogenic tumor rupture, mainly depends on
surgeon’s subjective judgment and active reporting. Serosal
invasion is a common pathological diagnosis in malignant
tumors but few mentioned in GIST before [16], the merits
of serosal invasion we selected in this study were less inter-
ference with subjective factors and surgical matters com-
pared with tumor rupture, easily observed in surgery and
feasibly confirmed by pathological diagnosis. But consider-
ing serosal invasion is not a standard prognostic factor in
GIST enrolled in the guidelines yet, it mostly depends on
detection and reporting by pathologists. Mitosis count is
also a strong prognostic factor in GIST and enrolled in
NIH criteria, but it still has limitations and its reliabil-
ity is controversial. Identification of mitoses should be
subjective, and the number detected depends on the
tissue fixation time and the magnification of the field
under the microscope [11].
Through univariate and multivariate analyses of the fac-
tors associated with RFS in test and validation cohort with
GIST, mitosis count > 10/50HPF and serosal invasion were
confirmed as the independent prognostic factors for the
Figure 4 Recurrence-free survival (RFS) in high-risk patients
with imatinib adjuvant therapy. (A) RFS by mitosis count > 10/50
HPF in patients with imatinib adjuvant therapy. (B) RFS by serosal
invasion in patients with imatinib adjuvant therapy.
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showed sub-dividing high-risk GIST patients by mitosis
count > 10/50HPF and serosal invasion yielded significantly
different outcomes and more effectively differentiated the
groups of GIST patients.
The prognostic accuracy of modified NIH criteria and
sub-groups based on modified NIH criteria were com-
pared using ROC analyses, mitosis count or serosal inva-
sion sub-group, produced better estimats for the risk of
GIST recurrence. The AUC was larger for the mitosis
count (0.890, 95% CI 0.841-0.968) or serosal invasion sub-Table 4 Multivariate analyses of factors associated with
recurrence-free survival (RFS) in GIST patients with
adjuvant imatinib therapy (*, P < 0.05)
Variable RFS hazard ratio (95% Cl) P value
Tumor size (≤10, > 10 cm) 0.801 (0.222-2.889) 0.736
Mitosis count (≤10, > 10/50 HPF) 1.944 (0.546-6.913) 0.307
Serosal invasion (Yes, No) 3.549 (1.047-12.025) 0.043*groups (0.905, 95% CI 0.858-0.940) than that for modified
NIH criteria in test cohort (0.860, 95% CI 0.807-0.902;
P < 0.01), and the results remained similar in the validation.
Criteria of prognostic indicator is always required the ac-
curacy as high as possible but the schemes as simple as
possible to meet various clinical cases. Our study demon-
strated two common factors, mitosis count > 10/50HPF
and serosal invasion. One of them already has been in-
cluded in high risk schemes of NIH criteria.
We further focused on whether mitosis count > 10/
50HPF or serosal invasion could affect efficiency of imatinib
adjuvant therapy. The results showed that GIST patients
with serosal invasion might suffer a poorer prognosis with
imatinib therapy, but there was no difference between pa-
tients with mitosis count > 10 and mitosis count ≤ 10/
50HPF in the RFS. Because of the limitation of the sample
numbers and follow-up time in our study, it still needs
more works to verify this result, but the high-risk GIST pa-
tients with serosal invasion should be noticed in clinical
follow-up because of higher possibility in recurrence even
with imatinib adjuvant therapy.
How to improve outcomes of GIST patients with se-
rosal invasion even after R0 resection is still a serious
problem. Should this kind of patients need more than 3-
year imatinib therapy? The real benefits and optimal
time to stop treatment still need further study and it
still remains the possibility of recurrence after stopping
taking the drugs. Neoadjuvant imatinib therapy, which
has been recommended by current ESMO and NCCN
guidelines for locally advanced GIST [17,18], may help
to improve the outcomes of GIST patients with serosal
invasion. Neoadjuvant imatinib therapy can shrink the
size of locally advanced GISTs and increase R0 resection
rate, which significantly prolong the RFS and OS com-
paring with the inoperable patients or patients with
palliative operation [19-23]. But there are still some
problems that need to be solved in future study: first,
how to verify serosal invasion of GISTs before surgery?
Serosal or subserosal invasion are as superficial infiltra-
tion different from typical locally advanced GIST which
can be judged by CT or MRI easily. It is hard for im-
aging examination to distinguish the real invasion or
tumor just leaning against adjacent organs or tissues; for
effective neoadjuvant therapy, aspiration biopsy is neces-
sary for not only diagnosis but also gene mutation detec-
tion for KIT and PDGFR, but conducting biopsies in
such highly malignant GIST may increase the risks of
tumor rupture or implantation metastasis.
Conclusions
In this study, we analyzed several “very high-risk” factors
in high-risk group of GIST patients after R0 resection.
Serosal invasion appears to improve the modified NIH
criteria and predicts an unfavorable outcome in high-
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Our study demonstrated the possibility of personalized
medical strategy for different GISTs by sub-dividing
high-risk patients.
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